HomeCompareEFL vs PFE

EFL vs PFE: Dividend Comparison 2026

EFL yields 23.17% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $5.6K in total portfolio value· pulled ahead in Year 10
10 years
EFL
EFL
● Live price
23.17%
Share price
$8.63
Annual div
$2.00
5Y div CAGR
-12.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.4K
Annual income
$1,306.58
Full EFL calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — EFL vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFLPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFL + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EFL pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFL
Annual income on $10K today (after 15% tax)
$1,969.87/yr
After 10yr DRIP, annual income (after tax)
$1,110.59/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $22,018.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFL + PFE for your $10,000?

EFL: 50%PFE: 50%
100% PFE50/50100% EFL
Portfolio after 10yr
$48.3K
Annual income
$14,258.56/yr
Blended yield
29.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

EFL
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFL buys
0
PFE buys
0
No recent congressional trades found for EFL or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFLPFE
Forward yield23.17%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-12.9%13.2%
Portfolio after 10y$45.4K$51.1K
Annual income after 10y$1,306.58$27,210.54
Total dividends collected$18.2K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EFL vs PFE ($10,000, DRIP)

YearEFL PortfolioEFL Income/yrPFE PortfolioPFE Income/yrGap
1$12,719$2,018.54$9,161$701.38+$3.6KEFL
2$15,699$2,089.82$8,610$859.79+$7.1KEFL
3$18,897$2,099.76$8,366$1,081.25+$10.5KEFL
4$22,278$2,057.50$8,483$1,405.66+$13.8KEFL
5$25,812$1,974.44$9,084$1,907.24+$16.7KEFL
6$29,481$1,862.18$10,418$2,732.78+$19.1KEFL
7$33,275$1,731.32$13,007$4,193.56+$20.3KEFL
8$37,195$1,590.75$18,010$7,005.87+$19.2KEFL
9$41,247$1,447.45$28,216$12,979.89+$13.0KEFL
10← crossover$45,440$1,306.58$51,081$27,210.54$5.6KPFE

EFL vs PFE: Complete Analysis 2026

EFLStock

Eaton Vance Floating-Rate 2022 Target Term Trust is a diversified, closed-end management investment company. The Trust’s investment objectives are high current income and to return $9.85 per share, the original net asset value per common share before deducting offering costs of $0.02 per common share, to holders of common shares of record on or about October 31, 2022. The Trust invests in various sectors including electronics/electrical, healthcare, business equipment and services, lodging and casinos, telecommunications, cable and satellite television, chemicals and plastics, oil and gas, industrial equipment, and drugs. The Trust's investment advisor is Eaton Vance Management.

Full EFL Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this EFL vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFL vs SCHDEFL vs JEPIEFL vs OEFL vs KOEFL vs MAINEFL vs JNJEFL vs MRKEFL vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.